DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vincristine (Vincristine) - Respiratory Failure - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Respiratory Failure ()

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include respiratory failure. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of    Next >>

Possible Vincristine side effects in 9 year old male

Reported by a physician from United States on 2012-08-17

Patient: 9 year old male

Reactions: Respiratory Failure, Disseminated Cryptococcosis, Septic Shock

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: weekly
    Indication: Acute Lymphocytic Leukaemia

Pegaspargase
    Dosage: single dose
    Indication: Acute Lymphocytic Leukaemia

Dexamethasone
    Dosage: daily
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in 63 year old male

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-30

Patient: 63 year old male

Reactions: Zygomycosis, Respiratory Failure

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin Hydrochloride
    Dosage: for 4 consecutive days
    Indication: Diffuse Large B-Cell Lymphoma

Prednisolone
    Dosage: at the time of admission

Cyclophosphamide
    Dosage: for 5 days
    Indication: B-Cell Lymphoma

Prednisolone
    Dosage: for 14 days
    Indication: B-Cell Lymphoma

Etoposide
    Dosage: for 4 consecutive days
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: for 4 consecutive days
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: for 6 days
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Vasopressor Unsp; Amlodipine; Atenolol; Antimycobacterials



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-27

Patient:

Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma

Adverse event resulted in: death

Drug(s) suspected as cause:
Epirubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone and Prednisone
    Indication: Diffuse Large B-Cell Lymphoma

Mabthera
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Respiratory Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Rituximab
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1 for chop and day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 for chop and day 2 for r-chop upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1 for chop and day 2 for r-chop
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in

Reported by a physician from Italy on 2012-07-20

Patient:

Reactions: Pneumonia, Respiratory Failure

Adverse event resulted in: death

Drug(s) suspected as cause:
Rituximab
    Dosage: on day 1

Doxorubicin HCL
    Dosage: 75% reduced r-chop

Prednisone
    Dosage: 75% reduced r-chop
    Administration route: Oral
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: 75% reduced r-chop
    Indication: Diffuse Large B-Cell Lymphoma

Cyclophosphamide
    Dosage: 75% reduced r-chop

Vincristine
    Dosage: 75% reduced r-chop

Prednisone
    Dosage: on days 1-5
    Administration route: Oral

Cyclophosphamide
    Dosage: on day 2
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 2, upto a maximum dose of 2 mg
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 2
    Indication: Diffuse Large B-Cell Lymphoma



Possible Vincristine side effects in 61 year old male

Reported by a consumer/non-health professional from Germany on 2012-07-13

Patient: 61 year old male

Reactions: Candida Pneumonia, Bronchopneumonia, Febrile Neutropenia, Respiratory Distress, Organising Pneumonia, Respiratory Failure, Interstitial Lung Disease, Pseudomonal Sepsis, Opportunistic Infection, Stenotrophomonas Sepsis, Tracheitis, Septic Shock, Sinusitis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Campath
    Dosage: 30 mg, qd
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-08

Pegfilgrastim
    Dosage: 6 mg, qd
    Start date: 2010-03-01
    End date: 2010-03-01

Cyclophosphamide
    Dosage: 1380 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07

Cyclophosphamide
    Dosage: 690 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Doxorubicin HCL
    Dosage: 92 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07

Vincristine
    Dosage: 2 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Start date: 2010-02-22
    End date: 2010-02-26

Doxorubicin HCL
    Dosage: 46 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Posaconazole
    Indication: Prophylaxis

Campath
    Dosage: 30 mg, qd
    Start date: 2010-02-22
    End date: 2010-02-23

Vincristine
    Dosage: 2 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-11

Pegfilgrastim
    Dosage: 3 mg, qd
    Indication: T-Cell Lymphoma



Possible Vincristine side effects in 61 year old male

Reported by a consumer/non-health professional from Germany on 2012-07-10

Patient: 61 year old male

Reactions: Respiratory Failure, Bronchopneumonia, Pseudomonal Sepsis, Febrile Neutropenia, Septic Shock, Tracheitis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 46 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Vincristine
    Dosage: 2 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07

Cyclophosphamide
    Dosage: 1380 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07

Cyclophosphamide
    Dosage: 690 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Pegfilgrastim
    Dosage: 3 mg, qd
    Indication: T-Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-11

Vincristine
    Dosage: 2 mg, unk
    Start date: 2010-02-22
    End date: 2010-02-22

Campath
    Dosage: 30 mg, qd
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-08

Posaconazole
    Indication: Prophylaxis

Campath
    Dosage: 30 mg, qd
    Start date: 2010-02-22
    End date: 2010-02-23

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Start date: 2010-02-22
    End date: 2010-02-26

Pegfilgrastim
    Dosage: 6 mg, qd
    Start date: 2010-03-01
    End date: 2010-03-01

Doxorubicin HCL
    Dosage: 92 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2010-01-07
    End date: 2010-01-07



Possible Vincristine side effects in male

Reported by a consumer/non-health professional from Germany on 2012-07-10

Patient: male, weighing 60.0 kg (132.0 pounds)

Reactions: Candida Pneumonia, Bronchopneumonia, Tachycardia, Atrial Fibrillation, Febrile Neutropenia, General Physical Health Deterioration, Lactic Acidosis, Respiratory Distress, Respiratory Failure, Skin Lesion, Pseudomonal Sepsis, Tracheitis, Septic Shock

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 92 mg, unk
    Indication: Peripheral T-Cell Lymphoma Unspecified
    Start date: 2010-01-07
    End date: 2010-01-07

Pegfilgrastim
    Dosage: 6 mg, once
    Start date: 2010-03-01
    End date: 2010-03-01

Cyclophosphamide
    Dosage: 690 mg, once
    Start date: 2010-02-22
    End date: 2010-02-22

Campath
    Dosage: 30 mg, qd
    Indication: Peripheral T-Cell Lymphoma Unspecified
    Start date: 2010-01-07
    End date: 2010-01-08

Vincristine
    Dosage: 2 mg, qd
    Start date: 2010-02-22
    End date: 2010-02-22

Vasopressin
    Dosage: unk
    Indication: Blood Pressure Management

Vincristine
    Dosage: 2 mg, unk
    Indication: Peripheral T-Cell Lymphoma Unspecified
    Start date: 2010-01-07
    End date: 2010-01-07

Cyclophosphamide
    Dosage: 1380 mg, unk
    Indication: Peripheral T-Cell Lymphoma Unspecified
    Start date: 2010-01-07
    End date: 2010-01-07

Doxorubicin HCL
    Dosage: 46 mg, once
    Start date: 2010-02-22
    End date: 2010-02-22

Campath
    Dosage: 30 mg, qd
    Start date: 2010-02-22
    End date: 2010-02-23

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: Peripheral T-Cell Lymphoma Unspecified
    Start date: 2010-01-07
    End date: 2010-01-11

Prednisone
    Dosage: 100 mg, qdx5
    Administration route: Oral
    Start date: 2010-02-22
    End date: 2010-02-26

Pegfilgrastim
    Dosage: 3 mg, qd
    Indication: Peripheral T-Cell Lymphoma Unspecified

Other drugs received by patient: Zienam; Posaconazole; Taranic; Zienam; Taranic; Candiohermal; Candiohermal



Possible Vincristine side effects in 73 year old male

Reported by a physician from Germany on 2012-07-06

Patient: 73 year old male

Reactions: Stenotrophomonas Infection, Febrile Neutropenia, Atrial Fibrillation, Ileus Paralytic, Multi-Organ Failure, Pneumonia Bacterial, Respiratory Failure, Cardiac Failure, Oesophagitis

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1500 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2009-06-25
    End date: 2009-09-03

Vincristine
    Dosage: 1 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2009-06-17
    End date: 2009-09-03

Prednisone
    Dosage: 100 mg, unk
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2009-06-17
    End date: 2009-09-10

Doxorubicin HCL
    Dosage: 100 mg, unk
    Indication: T-Cell Lymphoma
    Start date: 2009-06-25
    End date: 2009-09-03

Campath
    Dosage: 30 mg, q2w
    Indication: T-Cell Lymphoma
    Start date: 2009-06-25
    End date: 2009-09-04

Pegfilgrastim
    Dosage: 6 mg, q2w
    Indication: T-Cell Lymphoma
    Start date: 2009-06-29
    End date: 2009-09-06

Pegfilgrastim
    Indication: Prophylaxis

Other drugs received by patient: Ciprofloxacin



Possible Vincristine side effects in

Reported by a physician from Hungary on 2012-07-05

Patient:

Reactions: Pneumonia, Respiratory Failure

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Lymphoma

Prednisone TAB
    Indication: Lymphoma

Doxorubicin HCL
    Indication: Lymphoma

Vincristine
    Indication: Lymphoma



Possible Vincristine side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



Possible Vincristine side effects in

Reported by a physician from United States on 2012-06-28

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Vomiting, Stomatitis, Dyspnoea, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Respiratory Failure, Diarrhoea, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Vincristine side effects in 14 year old female

Reported by a physician from United States on 2012-06-28

Patient: 14 year old female, weighing 60.4 kg (132.9 pounds)

Reactions: Stomatitis, Hypotension, Encephalopathy, Acidosis, Hypercalcaemia, Respiratory Failure, Sepsis, Posterior Reversible Encephalopathy Syndrome, Hypocalcaemia, Enterocolitis, Cardiac Arrest

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Ambisome
    Dosage: unk
    Indication: Candida Test Positive
    Start date: 2012-05-20

Dexamethasone Sodium Phosphate
    Dosage: 10 mg/m2, bid or iv on days 1-5 and 15-19
    Administration route: Oral
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Mitoxantrone Hydrochloride
    Dosage: 10 mg/m2, over 30 minutes on days 1 and 2
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Pegaspargase
    Dosage: 2500 iu/m2 over 1 hr on days 3 and 17
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Cefepime
    Dosage: unk
    Indication: Klebsiella Infection
    Start date: 2012-05-10

Vincristine
    Dosage: 1.5 mg/m2 cyclic (max 2 mg) over i-5 minutes or infusion via mini bag on days 1, 8, i5 and 22
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Calcium Gluconate

Methotrexate
    Dosage: 8-15 mg (age based dosing) it on days 1 (or up to 72 hours prior to day 1) and 8
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30

Temsirolimus
    Dosage: 7.5 mg/m2, over 30 minutes on days i, 8 and 15 (max dose: 15 mg)
    Indication: B Precursor Type Acute Leukaemia
    Start date: 2012-04-30



Possible Vincristine side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-25

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Stomatitis, Vomiting, Dyspnoea, Nausea, Gastrointestinal Toxicity, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Dexamethasone
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone TAB
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Dexamethasone
    Dosage: on days 1-5 of cycle 2,4 and 6

Other drugs received by patient: Unknown Medication; Leucovorin Calcium; Filgrastim



Possible Vincristine side effects in 46 year old female

Reported by a individual with unspecified qualification from Germany on 2012-06-21

Patient: 46 year old female

Reactions: Mucosal Inflammation, Respiratory Failure, General Physical Health Deterioration, Haemorrhagic Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Vincristine
    Indication: non-Hodgkin's Lymphoma

Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Prednisone TAB
    Indication: non-Hodgkin's Lymphoma

Mabthera
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-05

Patient: male, weighing 102.6 kg (225.7 pounds)

Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: 1600 mg, cyclic
    End date: 2011-07-28

Adriamycin PFS
    Dosage: 101 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-05

Rituximab
    Dosage: 750 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Methotrexate
    Dosage: 400 mg, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-27

Cytarabine
    Dosage: 6 g, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-30

Dexamethasone
    Dosage: 40 mg, cyclic
    Indication: Mantle Cell Lymphoma

Dexamethasone
    Dosage: 20 unk, unk
    Administration route: Oral
    End date: 2011-07-15

Vincristine
    Dosage: 2 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-12

Velcade
    Dosage: 2.6 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Cyclophosphamide
    Dosage: 603 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-02
    End date: 2011-07-04

Other drugs received by patient: Filgrastim; Ferrous Sulfate TAB; Heparin; Senokot; Triamcinolone Acetonide; Compazine; Ciprofloxacin; Fluconazole; Omeprazole; Mesna; Prevident; Valtrex; Vitamin C / 00008001 /; Methylprednisolone; Periogard; Ultram; Vitamin D



Possible Vincristine side effects in female

Reported by a individual with unspecified qualification from United States on 2012-05-25

Patient: female, weighing 14.9 kg (32.8 pounds)

Reactions: Anaemia, Hyponatraemia, Rash, Pyrexia, Ascites, Abdominal Pain Upper, Abdominal Compartment Syndrome, Respiratory Failure, Pneumonia Herpes Viral, Bone Marrow Failure, Neutropenia, Thrombocytopenia, Cardiac Arrest, Septic Shock, Infection in AN Immunocompromised Host

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Vincristine
    Dosage: .99 mg

Methotrexate
    Dosage: 24.5 mg

Dexamethasone
    Dosage: 17.5 ml

Mercaptopurine
    Dosage: 460 mg



Possible Vincristine side effects in 46 year old female

Reported by a individual with unspecified qualification from Germany on 2012-05-04

Patient: 46 year old female

Reactions: Mucosal Inflammation, Respiratory Failure, General Physical Health Deterioration, Haemorrhagic Ascites

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Mabthera
    Indication: non-Hodgkin's Lymphoma

Doxorubicin Hydrochloride
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Prednisone
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma



Possible Vincristine side effects in 79 year old female

Reported by a individual with unspecified qualification from Portugal on 2012-04-27

Patient: 79 year old female

Reactions: Pneumonia, Hyperbilirubinaemia, Respiratory Failure, Hepatitis Acute, Urosepsis, General Physical Health Deterioration, Encephalopathy, non-Hodgkin's Lymphoma Recurrent, Hepatitis B

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: non-Hodgkin's Lymphoma

Cyclophosphamide
    Indication: non-Hodgkin's Lymphoma

Vincristine
    Indication: non-Hodgkin's Lymphoma

Methotrexate
    Indication: non-Hodgkin's Lymphoma

Dexamethasone
    Indication: non-Hodgkin's Lymphoma

Rituximab
    Indication: non-Hodgkin's Lymphoma

Bleomycin Sulfate
    Indication: non-Hodgkin's Lymphoma

Prednisolone
    Indication: non-Hodgkin's Lymphoma

Other drugs received by patient: Acarbose; Allopurinol; Omeprazole; Betahistine; Trimetazidine



Possible Vincristine side effects in male

Reported by a physician from United States on 2012-04-18

Patient: male, weighing 102.6 kg (225.7 pounds)

Reactions: Cardio-Respiratory Arrest, Respiratory Failure, Anaemia, Troponin I Increased, Thrombocytopenia, Infection

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Adriamycin PFS
    Dosage: 101 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-05

Velcade
    Dosage: 2.6 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Methotrexate
    Dosage: 400 mg, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-27

Methotrexate
    Dosage: 1600 mg, cyclic
    End date: 2011-07-28

Cytarabine
    Dosage: 6 g, cyclic
    Indication: Mantle Cell Lymphoma
    End date: 2011-07-30

Dexamethasone
    Dosage: 20 unk, unk
    Administration route: Oral
    End date: 2011-07-15

Dexamethasone
    Dosage: 40 mg, cyclic
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: 603 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-02
    End date: 2011-07-04

Vincristine
    Dosage: 2 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-05
    End date: 2011-07-12

Rituximab
    Dosage: 750 mg, cyclic
    Indication: Mantle Cell Lymphoma
    Start date: 2011-07-01
    End date: 2011-07-26

Other drugs received by patient: Periogard; Senokot; Compazine; Triamcinolone Acetonide; Valtrex; Fluconazole; Prevident; Ferrous Sulfate TAB; Filgrastim; Ciprofloxacin Hydrochloride; Heparin; Methylprednisolone; Vitamin C / 00008001 /; Vitamin D; Omeprazole; Ultram; Mesna



Possible Vincristine side effects in 59 year old female

Reported by a health professional (non-physician/pharmacist) from Germany on 2012-04-13

Patient: 59 year old female

Reactions: Renal Failure, Respiratory Failure, T-Cell Lymphoma

Adverse event resulted in: death, disablity

Drug(s) suspected as cause:
Doxorubicin HCL
    Dosage: 100 mg, once
    Indication: T-Cell Lymphoma
    Start date: 2011-09-16
    End date: 2011-09-16

Vincristine
    Dosage: 2 mg, once
    Indication: T-Cell Lymphoma
    Start date: 2011-09-16
    End date: 2011-09-16

Campath
    Dosage: 30 mg, once
    Indication: T-Cell Lymphoma
    Start date: 2011-09-16
    End date: 2011-09-16

Cyclophosphamide
    Dosage: 1500 mg, once
    Indication: T-Cell Lymphoma
    Start date: 2011-09-16
    End date: 2011-09-16

Prednisone TAB
    Dosage: 100 mg, qdx5
    Administration route: Oral
    Indication: T-Cell Lymphoma
    Start date: 2011-09-16
    End date: 2011-09-20



Possible Vincristine side effects in 18 year old male

Reported by a physician from United States on 2012-02-21

Patient: 18 year old male, weighing 72.0 kg (158.4 pounds)

Reactions: Respiratory Failure, Platelet Count Decreased, Herpes Zoster, Klebsiella Sepsis

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Methotrexate
    Dosage: ;x1; inth ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-29

Methotrexate
    Dosage: ;x1; inth ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2012-01-13
    End date: 2012-01-13

Prednisone TAB
    Dosage: 20 ug/ m**2; bid; po
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29

Vincristine
    Dosage: 1.5 mg/ m**2; qw; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2012-01-28

Velcade
    Dosage: 1.3 mg/m**2; qd; iv
    Indication: Acute Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-30

Cytarabine
    Dosage: ;x1; inth
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-29

Oncaspar
    Dosage: 2500 iu/m2; qw; im
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2012-01-28

Doxorubicin HCL
    Dosage: 60 mg/ m**2; qd; iv
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29
    End date: 2011-12-30

Hydrocortisone
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-12-29



Possible Vincristine side effects in

Reported by a individual with unspecified qualification from Japan on 2012-01-11

Patient:

Reactions: Respiratory Failure, Multiple-Drug Resistance, Pulmonary Alveolar Haemorrhage

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Dexamethasone TAB
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Lenalidomide
    Dosage: 25 mg on days 1-21
    Indication: Multiple Myeloma

Prednisolone
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Thalidomide
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Melphalan Hydrochloride
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Dexamethasone TAB
    Dosage: 40 mg, (day 1, 8, 15, 22), 4 weekly

Bortezomib
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Vincristine
    Dosage: unk, unknown
    Indication: Multiple Myeloma

Doxorubicin HCL
    Dosage: unk, unknown
    Indication: Multiple Myeloma



Possible Vincristine side effects in 35 year old female

Reported by a physician from Japan on 2011-11-30

Patient: 35 year old female

Reactions: Tumour Lysis Syndrome, Drug Ineffective, Respiratory Failure, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chemotherapy

Methotrexate
    Indication: Chemotherapy

Doxorubicin HCL
    Indication: Chemotherapy

Morphine
    Indication: Bone Pain

Vincristine
    Indication: Chemotherapy



Possible Vincristine side effects in 35 year old female

Reported by a physician from Japan on 2011-11-29

Patient: 35 year old female

Reactions: Tumour Lysis Syndrome, Respiratory Failure, Drug Ineffective, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Chemotherapy

Morphine
    Indication: Bone Pain

Cyclophosphamide
    Indication: Chemotherapy

Vincristine
    Indication: Chemotherapy

Methotrexate
    Indication: Chemotherapy



Possible Vincristine side effects in 35 year old female

Reported by a individual with unspecified qualification from Japan on 2011-11-25

Patient: 35 year old female

Reactions: Hyperkalaemia, Disseminated Intravascular Coagulation, Pulmonary Alveolar Haemorrhage, Breast Atrophy, Lactic Acidosis, Haemodialysis, Tumour Lysis Syndrome, Respiratory Failure, Ventricular Fibrillation, Cardiac Arrest

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 800 mg/m2
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: 40 mg/m2
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: 2 mg/kg
    Indication: Burkitt's Lymphoma



Possible Vincristine side effects in 35 year old female

Reported by a health professional (non-physician/pharmacist) from Japan on 2011-11-17

Patient: 35 year old female

Reactions: Tumour Lysis Syndrome, Respiratory Failure, Disseminated Intravascular Coagulation, Ventricular Fibrillation, Cardiac Arrest

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Doxorubicin HCL
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma



Possible Vincristine side effects in 11 year old female

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-28

Patient: 11 year old female, weighing 35.0 kg (77.0 pounds)

Reactions: Abdominal Pain, Hepatic Function Abnormal, Hypersensitivity, Pain, Rectal Haemorrhage, Extrasystoles, Coagulopathy, Headache, Skin Hyperpigmentation, Caecitis, Erythema, Multi-Organ Failure, Dyspepsia, Chest Pain, Renal Failure Acute, Heart Rate Abnormal, Anuria, Pain in Extremity, Hypotension, Musculoskeletal Pain, Atrial Fibrillation, Rash, Arrhythmia, Acute Lymphocytic Leukaemia, Mucosal Inflammation, Oral Pain, Respiratory Failure, Rash Erythematous, Heart Rate Increased, Electrocardiogram P Wave Abnormal

Adverse event resulted in: death

Drug(s) suspected as cause:
Evoltra
    Dosage: 48 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-06-17
    End date: 2011-06-21

Dexamethasone
    Dosage: 6 mg, bid
    Administration route: Oral
    Start date: 2011-05-26
    End date: 2011-06-08

Dexamethasone
    Dosage: 6 mg, bid
    Administration route: Oral
    Start date: 2011-06-17
    End date: 2011-06-23

Cytarabine
    Dosage: 30 mg, 1x/w
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-11
    End date: 2011-06-08

Methotrexate
    Dosage: 12 mg, 1x/w
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-11
    End date: 2011-06-22

Etoposide
    Dosage: 120 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-12
    End date: 2011-05-16

PEG-Asparaginase
    Dosage: 1200 iu, q2w
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-12
    End date: 2011-05-26

Hydrocortisone
    Dosage: 12.5 mg, 1x/w
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-11
    End date: 2011-06-08

Vincristine
    Dosage: 1.7 mg, 1x/w
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-12
    End date: 2011-06-02

Cyclophosphamide
    Dosage: 360 mg, qd
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-06-17
    End date: 2011-06-21

Dexamethasone
    Dosage: 6 mg, bid
    Administration route: Oral
    Indication: Acute Lymphocytic Leukaemia
    Start date: 2011-05-12
    End date: 2011-05-18

Etoposide
    Dosage: 120 mg, qd
    Start date: 2011-06-17
    End date: 2011-06-21

Dexamethasone
    Dosage: 6 mg, bid
    Administration route: Oral
    Start date: 2011-07-01
    End date: 2011-07-07

Other drugs received by patient: Allopurinol; Cotrim; Levomepromazine; Piperacillin W; Acetaminophen; Ambisome; Acetaminophen; Allopurinol; Ondansetron; Ciprofloxacin; Levomepromazine; Omeprazole; Ondansetron; Penicillin V; Cotrim; Metronidazole



Possible Vincristine side effects in 73 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2011-10-24

Patient: 73 year old male

Reactions: Pneumonia, Cerebral Infarction, Respiratory Failure, Superior Sagittal Sinus Thrombosis, Blindness

Drug(s) suspected as cause:
Daunorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Prednisolone
    Indication: Acute Lymphocytic Leukaemia

Asparaginase
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia



Possible Vincristine side effects in 12 year old female

Reported by a health professional (non-physician/pharmacist) from Turkey on 2011-10-12

Patient: 12 year old female

Reactions: Bronchopulmonary Aspergillosis, Electrocardiogram QT Prolonged, White Blood Cell Count Decreased, Hepatic Lesion, Pyrexia, Hypokalaemia, Respiratory Failure, Hypomagnesaemia, Chest Pain, Neutrophil Count Decreased, Cough

Drug(s) suspected as cause:
Voriconazole

Doxorubicin HCL
    Indication: Acute Lymphocytic Leukaemia

Vincristine
    Indication: Acute Lymphocytic Leukaemia

Elspar
    Indication: Acute Lymphocytic Leukaemia

Imatinib Mesylate
    Indication: Acute Lymphocytic Leukaemia

Cytarabine
    Indication: Acute Lymphocytic Leukaemia

Prednisolone
    Dosage: unk
    Indication: Acute Lymphocytic Leukaemia

Other drugs received by patient: Magnesium; Ciprofloxacin; Lidocaine; Potassium



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014